Transcript Diapositiva 1

NOT ALL PAST SUCCESSES IN CANCER RESEARCH
HAVE BEEN FOLLOWED BY ACTIONS
EUROCHIP-2 THE ACTION
Project & news
Public Health Program
EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE - GENERAL
www.tumori.net/eurochip
WHAT IS THE EUROCHIP-2 THE ACTION PROJECT?
• It is a translational research project
(from epidemiology to public health)
• It is a project against disparities
• It is an EC project
• It aims to research ways to promote health by
EU imprimatur
• Its goal is to promote public health actions
against cancer in each EU country
• It works in the building of an European platform
for cancer control
EUROPE WITHIN THE WORLD
AGE-STANDARDIZED INCIDENCE RATES
Source: GLOBOCAN 2002, IARC. Age-Standardised (World) rates, per 100,000
EUROPE WITHIN THE WORLD
AGE-STANDARDIZED MORTALITY RATES
Source: GLOBOCAN 2002, IARC. Age-Standardised (World) rates, per 100,000
All cancers combined: Europe
5-year age-adj. relative survival trend in male
Polish
Slovakia
Estonia
Slovenia
Scotland
Wales
1.8
Polish
1984
-2.3
1993-1984
5.2
7.2
8.7
7.9
6.3
8.8
8.9
6.6
30
4.5
Scotland
6.4
1993-1984
4.0
7.5
7.5
6.8
7.4
Norvay
4.7
Iceland
4.5
Finland
7.3
German
6.4
6.7
Spanish
Dutch
10.5
Sweden
6.3
5.2
7.5
Swiss
6.5
8.5
French
8.0
12.1
20
Slovakia
Europe
Italian
9.2
10
3.9
Slovenia
English
4.5
0
1984
Wales
3.5
German
French
Dutch
Swiss
Sweden
Iceland
3.9
Estonia
6.6
Denmark
English
Italian
Europe
Spanish
Finland
Norway
5-year age-adj. relative survival trend in female
40
Relative survival
50
60
9.5
0
10
20
30
40
Relative survival
50
60
Differences in Europe. Relative risks (Max/Min).
All cancers combined
Year
Males
Females
1985
2.3
1.8
1996
4.3
1.9
1985
1.9
1.9
1996
1.9
2.2
1985-89
2.2
2.0
1990-94
2.5
2.0
Mortality
Incidence
5-yrs Survival
Data from cancer registries of these countries
Austria, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania,
Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Sources: EUROCIM - EUROCARE
GDP (1997) and 5-year cancer survival
Disks are proportional to the national health expenditure ($ PPP)
$ PPP: Parity Purchasing Power per capita (US $) Sourcesi: OECD 2002 and EUROCARE-3
INDICATOR
A
INDICATOR
B
INDICATOR
C
.
.
.
INDICATOR
Z
ANALYSIS
GENERAL AIMS OF EUROCHIP-2
1. To extend the collaboration
2. To promote national groups in each country
3. To analyse the behaviour of available
indicators
4. To discuss on deficiencies at national and
international level
5. To promote at least one important ACTION in
each country
EUROCHIP-2: MAP
EUROCHIP-2 DISCUSSION PLAN
COUNTRY 1
A
C
T
I
O
N
1
A
C
T
I
O
N
2
A
C
T
I
O
N
3
COUNTRY 2
A
C
T
I
O
N
3
A
C
T
I
O
N
4
COUNTRY 3
COUNTRY 30
A
C
T
I
O
N
5
A
C
T
I
O
N
6
A
C
T
I
O
N
4
A
C
T
I
O
N
6
EUROPEAN PUBLIC
HEALTH ACTION –
early diagnosis
EUROPEAN PUBLIC
HEALTH ACTION –
care & treatment
EUROPEAN PUBLIC
HEALTH ACTION prevention
Cervical screening
Pilot studies
Dietary prevention
EU CANCER PLAN
UTERUS CANCER STANDARDIZED MORTALITY RATE
AGE: 20 – 44 (IN THESE AGES MOSTLY CERVICAL CANCER)
http://epicancer.iss.it
European standard per 100,000
EUROCHIP-2 ACTION:
TASK FORCE ON CERVICAL CANCER SCREENING
AIMS
- Describe the opportunistic/programmed cervical cancer
screening in those countries at present time
- For countries without cervical screening programs: find
difficulties and problems with specific assessment
studies in these Eastern European countries
- For countries with cervical screening programs: to help
specific activities that at the moment are not subsidize
- To create relations with groups of pressure with national
health ministries and with European Parliament
- To share information with other networks (EUNICE,
European Cancer Screening networks)
ASSESSMENT PHASES:
COLLECTION OF INFO ON
• Use of Policies, Guidelines, and Norms
• Program Management Issues
• Health Services
• Information and Education Activities
• Community Perspectives
• Laboratory
• Information Systems
Screening prices
VS
treatment prices
• In Bulgaria the mean value of programme screening for 1
person is around 5 €
• Target population: 1.8 million (age 25-60)
BULGARIAN
ESTIMATES
• Screening interval: 3 years
• 5 € * 0.6 million = 3 million € per year
Number of cases
in Bulgaria (2001)
St. III – IV
Prices according to EU data
(Andrae Bengt - 2004)
Per item
Total
347
30 000 €
10 410 000 €
St. I – II
670
9 000 €
6 030 000 €
CIS
275
300 €
83 500 €
Total
1292
-
16 522 500 €
V. Zlatkov - Bulgaria (2006)
Cervical cancer
stages
PROBLEMS OF THE ORGANISED
SCREENING PROGRAM
• Low participation: Only 21.7% of the 12,960 invited women
attended the screening
• No funds for screening registry
• No invitation of women without insurance (~5% of population)
•
•
•
To use experience from other countries to produce
successful campaigns
Group of pressure for invitation of women without insurance
Money for starting the organization of screening registry
P. Veerus - Estonia (2006)
EUROCHIP FUND
1. Budget: 17.500 € - Only for personnel costs
2. Involvement of personnel for
ACTIONS
3. Money sent:
• Directly to personnel
OR
• To Institute involved in the project
4. Necessary admin. documentation (at the end of the work)
• Declaration of money receipt (by personnel)
• Declaration of personnel payment (by Institute)
EUROCHIP-2 FUNDS:
THE ACTION IN LATVIA